Dianthus Therapeutics (DNTH) EPS (Weighted Average and Diluted) (2020 - 2025)
Dianthus Therapeutics (DNTH) recorded quarterly EPS (Weighted Average and Diluted) of -$0.97 in Q3 2025, down 10.23% quarter-over-quarter from -$0.88 in Q2 2025, and down 31.08% on a YoY basis from -$1.41 in Q3 2024.
Dianthus Therapeutics (DNTH) EPS (Weighted Average and Diluted) (2020 - 2025) Analysis & Trends
Dianthus Therapeutics' EPS (Weighted Average and Diluted) history runs 6 years deep, the most recent figure standing at -$0.97 for Q3 2025.
- In Q3 2025, EPS (Weighted Average and Diluted) fell 31.08% year-over-year to -$0.97; the TTM figure through Sep 2025 stood at -$3.49 (down 148.74% YoY), while the FY2024 annual figure was -$2.55, up 69.82% from the prior year.
- EPS (Weighted Average and Diluted) was -$0.97 for Q3 2025 at Dianthus Therapeutics, down from -$0.88 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $8.95 in Q4 2023 to a low of -$12.73 in Q2 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$2.28 across 5 years, with a median of -$0.74 in 2024.
- Biggest YoY gain for EPS (Weighted Average and Diluted) was 177.36% in 2023; the steepest drop was 4289.66% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.32 in 2021, then sank by 3515.62% to -$11.57 in 2022, then surged by 177.36% to $8.95 in 2023, then tumbled by 109.16% to -$0.82 in 2024, then dropped by 18.29% to -$0.97 in 2025.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.97 (Q3 2025), -$0.88 (Q2 2025), and -$0.82 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Dianthus Therapeutics | 3.60 Bn | 3.19 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -0.97 |
| Jun 30, 2025 | -0.88 |
| Mar 31, 2025 | -0.82 |
| Dec 31, 2024 | -0.82 |
| Sep 30, 2024 | -0.74 |
| Jun 30, 2024 | -0.51 |
| Mar 31, 2024 | -0.54 |
| Dec 31, 2023 | 8.95 |
| Sep 30, 2023 | -3.78 |
| Jun 30, 2023 | -12.73 |
| Mar 31, 2023 | -8.10 |
| Dec 31, 2022 | -11.57 |
| Sep 30, 2022 | -8.90 |
| Jun 30, 2022 | -0.29 |
| Mar 31, 2022 | -0.39 |
| Dec 31, 2021 | -0.32 |
| Sep 30, 2021 | -0.30 |
| Jun 30, 2021 | -0.32 |
| Mar 31, 2021 | -0.36 |
| Dec 31, 2020 | -0.41 |